IL28B polymorphisms and chronic hepatitis C;Polymorphisme de l'IL28B et hepatite chronique C

Gastroenterologie Clinique et Biologique

Volumn 34, Issue 11, 2010, Pages 587-589

  Chevaliez, S ^a,b   Hezode C ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 29; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ALLELE; AUTOSOMAL DOMINANT INHERITANCE; CHROMOSOME 19; CLINICAL TRIAL; DISEASE ASSOCIATION; DNA POLYMORPHISM; GENE; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; IL28B GENE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; RACE; SHORT SURVEY; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; INTERLEUKINS; POLYETHYLENE GLYCOLS; POLYMORPHISM, GENETIC; RIBAVIRIN; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 78649447153     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2010.06.008     Document Type: Short Survey

References (13)

1. Ge D., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461(7262):399-401.
2. Thomas D.L., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461(7265):798-801.
3. Suppiah V., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41(10):1100-1104.
4. Tanaka Y., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41(10):1105-1109.
5. McCarthy JJ, et al. Replicated association between an interleukin-28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010;138(7):2307-14.
6. Rauch A, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138(4):1338-45.
7. Neumann A., et al. IL28B polymorphism is significantly correlated with IFN anti-viral effectiveness on first day of pegylated interferon-alpha and ribavirin therapy of chronic HCV infection. J Hepatol 2010, 52(Suppl. 1):S468.
8. Mangia A., et al. Predictive role of IL28B C/C genotype on SVR and RVR in patients with genotype 2/3 chronic infection. J Hepatol 2010, 52(Suppl. 1):S56.
9. Asselah T., et al. A chromosome 19 SNP (rs12979860) predicts outcome (EVR/SVR) in HCV patients treated with interferon, independent of pegylation or ribavirin. J Hepatol 2010, 52(Suppl.1):S456.
10. Chevaliez S., Pawlotsky J.M. Interferon-based therapy of hepatitis C. Adv Drug Deliv Rev 2007, 59(12):1222-1241.
11. Marcello T., et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006, 131(6):1887-1898.
12. Dill M.T., et al. IFN stimulated geen expression in the liver is a better predictor of treatment response in chronic hepatitis C than the IL28B (IFNlambda3) genotype. J Hepatol 2010, 52(Suppl. 1):S461.
13. Thompson AJ, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139.